Article

Prostatitis carries a high price--in more ways than one

Chronic prostatitis carries a high price-both on the health care system and society in general. Two separate studies demonstrate those costs may be 1.7 times higher than for men without prostatitis and perhaps 1.5 times higher than for another debilitating chronic pain syndrome, rheumatoid arthritis.

Related Videos
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
1 expert is featured in this series.
Case 2: A 63-Year-Old Man With Recurrent HSPC
1 expert is featured in this series.
Comorbidities and Adherence: Tailoring mHSPC Treatment
FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Related Content
Man talking with doctor | Image Credit: © Pcess609 - stock.adobe.com
May 22nd 2025

Case study: 69-year-old Black man with mHSPC

Urology Times staff
"When we select abiraterone for our patients with mHSPC, there's a choice between generic and branded options," says Paul C. Dato MD.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
May 21st 2025

FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk

Hannah Clarke
The committee voted 4-5 in opposition of a favorable benefit-risk profile.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
May 20th 2025

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Hannah Clarke
The phase 3 study design will now be submitted for final review by the agency.
Woman talking with a doctor | Image Credit: © pucko_ns - stock.adobe.com
May 20th 2025

Experts share insights on next-generation NMIBC therapies

Urology Times staff
A recent Urology Times Clinical Forum provided an in-depth overview of current and emerging strategies for managing NMIBC.
© 2025 MJH Life Sciences

All rights reserved.